Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.
about
15 YEARS OF PARAGANGLIOMA: Clinical manifestations of paraganglioma syndromes types 1-5Murine models and cell lines for the investigation of pheochromocytoma: applications for future therapies?Current views on cell metabolism in SDHx-related pheochromocytoma and paragangliomaImaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG.Renaissance of (18)F-FDG positron emission tomography in the imaging of pheochromocytoma/paraganglioma.Current approaches and recent developments in the management of head and neck paragangliomas.Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatmentMetastatic paraganglioma.Combined PET/CT by 18F-FDOPA, 18F-FDA, 18F-FDG, and MRI correlation on a patient with Carney triad.Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphyAssociation of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes.Succinate dehydrogenase gene mutations in cardiac paragangliomasDiagnostic Performance of (68)Ga-DOTATATE PET/CT, (18)F-FDG PET/CT and (131)I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma.Results of a prospective multicenter neuroendocrine tumor registry reporting on clinicopathologic characteristics of Greek patients.Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.Pheochromocytoma and paraganglioma: current functional and future molecular imaging.Imaging of adrenal masses with emphasis on adrenocortical tumors.Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma.Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.The genetic basis of pheochromocytoma and paraganglioma: implications for managementCurrent role of metaiodobenzylguanidine in the diagnosis of pheochromocytoma and medullary thyroid cancer.Inhibitory Effect of the Noncamptothecin Topoisomerase I Inhibitor LMP-400 on Female Mice Models and Human Pheochromocytoma CellsFalse-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease.Pheochromocytoma - update on disease management.18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study.18F-DOPA PET/CT unravels malignant paraganglioma mimicking temporomandibular joint disorderUsefulness of [18F]-DA and [18F]-DOPA for PET imaging in a mouse model of pheochromocytomaCurrent and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma.EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma.Counseling patients with succinate dehydrogenase subunit defects: genetics, preventive guidelines, and dealing with uncertainty.68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRISpectrum of retroperitoneal and genitourinary paraganglioma: Experience at a North Indian tertiary care center.Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by (18) F-FDOPA PET: focus on missed lesions.Rapidly Growing Chest Wall Mass in a Case of Sporadic Metastatic Paraganglioma: Imaging With 4 Different PET Radiopharmaceuticals.MIBG molecular imaging for evaluating response to chemotherapy in patients with malignant pheochromocytoma: preliminary results.Comparison of clinical and imaging features in succinate dehydrogenase-positive versus sporadic paragangliomasMolecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomasGenotype-specific abnormalities in mitochondrial function associate with distinct profiles of energy metabolism and catecholamine content in pheochromocytoma and paraganglioma.(68)Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity.Current and future trends in the anatomical and functional imaging of head and neck paragangliomas.
P2860
Q26798384-D82D6E1A-A7AA-418B-85D6-68AA71D5ACC3Q26828446-0D624E71-F81F-4EA5-9478-B7FC22807266Q33590969-EFAEF88F-2C88-4DDA-A3B4-C1F70D170CB8Q33812606-0EA65B86-EBF5-4DA2-8735-E4594B08D745Q33837098-F2A2A089-D012-41E5-8B55-0ED21EA50260Q34204524-D237303D-FD30-42F7-A70A-4CA0DDA4E5D2Q34410500-88C2F8A7-62A3-45D7-B866-271D00E1DFD9Q34480015-8F28DA18-B4B6-47C4-9798-3D1ABB6E068CQ34663708-DF24D7F3-8E1C-4512-9EC7-F3D58881BE09Q35198539-7DB9964B-4A0B-4504-9287-9BB93A38E77DQ35562799-2BE73CAC-2EB7-4B81-843B-DF05E17F2657Q35668495-0FD7993C-76CE-46E7-943A-7E57F44484BAQ35724965-D66C6A90-DE23-4F34-8B43-BC19BB57CC24Q35922755-58D1DB94-DBDE-407A-BC62-D457E3BD80BBQ35925505-103A4A55-BDF3-48AB-95B1-C14AE6B5C341Q35972320-DEFFB90E-6DE8-42C8-AA64-9BD684522B46Q35999562-14BD9F16-2EDD-4A6F-B740-3A544FB0120EQ36021577-AD95929F-2925-4E23-AFE9-568523F3CEC7Q36024376-F3A3FB84-F3AF-4EC4-8A41-74B70BB1600BQ36067684-97B39832-1F02-43F9-93E0-72F2A73B8653Q36152379-01F249A3-BD22-41F4-AEEE-0BC6B5F67720Q36164329-1802F49B-8AAD-4537-A595-ADCF9E3AABF8Q36167038-8CCA4622-8F17-40C8-94A6-EB52C3C4907CQ36328071-4DFB1653-B545-4CE6-9829-FCAAF637E0B1Q36342833-18A8A535-90B8-40B3-B855-BBA01ABDCCFBQ36461269-D65BE388-A6F2-4E17-99E3-2396E5B1D3BCQ36463116-E41AEE9A-3267-4A5A-B16B-4D1C06CB7AE0Q36467134-5270F3BA-9D25-46E5-865F-223B34B4EEE5Q36467722-455678F6-DD4C-472E-A708-0D46BD5FE47DQ36477785-DD8825DD-19BB-4DC1-8279-C951BA9B33E6Q36535747-73340F61-C91D-4547-9B67-C61B6374FE74Q36547486-742B8C35-8B94-46A7-AA82-C58A211946BAQ36724520-E7CD0D4C-D5B1-4FF8-8CF5-A0DD63C420C8Q36772379-EE3E74EE-EE85-4889-B293-0D8E52E209D6Q36776978-4E4CB850-CA93-4514-97DF-F820577CD215Q36793727-2DA809F7-EF19-495C-8FB4-6F2D867BE4BFQ36804496-C95034C0-9B85-4707-8DB1-13F5A78CCE9DQ37025126-22739C1F-6C25-4131-B584-C5D8E4E77957Q37185143-E54B4323-8536-40D3-81F7-D95D69DE95ECQ37220182-A8D4D268-4195-4CA9-818C-4D5F13192D93
P2860
Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Comparison of 18F-fluoro-L-DOP ...... hromocytoma and paraganglioma.
@en
Comparison of 18F-fluoro-L-DOP ...... hromocytoma and paraganglioma.
@nl
type
label
Comparison of 18F-fluoro-L-DOP ...... hromocytoma and paraganglioma.
@en
Comparison of 18F-fluoro-L-DOP ...... hromocytoma and paraganglioma.
@nl
prefLabel
Comparison of 18F-fluoro-L-DOP ...... hromocytoma and paraganglioma.
@en
Comparison of 18F-fluoro-L-DOP ...... hromocytoma and paraganglioma.
@nl
P2093
P2860
P356
P1476
Comparison of 18F-fluoro-L-DOP ...... hromocytoma and paraganglioma.
@en
P2093
Alexander Ling
Bastiaan Havekes
Clara C Chen
Graeme Eisenhofer
Henri J L M Timmers
Jorge A Carrasquillo
Karen T Adams
Lucia Martiniova
Millie Whatley
P2860
P304
P356
10.1210/JC.2009-1248
P407
P50
P577
2009-10-28T00:00:00Z